AZN

S.Korea begins preliminary review of AstraZeneca's COVID-19 vaccine candidate

Credit: REUTERS/DADO RUVIC

South Korea's food and drug ministry said on Tuesday it had begun a preliminary review of a COVID-19 vaccine being developed by AstraZeneca PLC for potential fast-track approval.

SEOUL, Oct 27 (Reuters) - South Korea's food and drug ministry said on Tuesday it had begun a preliminary review of a COVID-19 vaccine being developed by AstraZeneca PLC AZN.L for potential fast-track approval.

The Ministry of Food and Drug Safety said in a statement that it had formed a screening team to review the vaccine candidate, with an application for formal approval expected in 90 days under its rapid approval programme for COVID-19 treatments and vaccines.

The team is reviewing the vaccine's non-clinical test data, the ministry said.

The ministry added that it had given a green light to some 26 clinical trials for COVID-19 treatments and vaccines as of Monday, by entities such as pharmaceutical companies Celltrion Inc 068270.KS and Genexine Inc 095700.KQ, with seven completed and 19 ongoing.

(Reporting by Joyce Lee; Editing by Kirsten Donovan)

((jungyoon.lee@tr.com; +82 2 6936 1467;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AZN

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More